(Q38612672)

4 September 2017

Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us? (English)

1 reference

4 September 2017

1

1 reference

PubMed ID

26486979

4 September 2017

language of work or name

1 reference

1 November 2015

1 reference

Journal of Feline Medicine and Surgery

4 September 2017

1 reference

4 September 2017

17

1 reference

4 September 2017

11

1 reference

4 September 2017

925-939

1 reference

Feline immunodeficiency. ABCD guidelines on prevention and management.

4 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Feline leukaemia. ABCD guidelines on prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

2008 American Association of Feline Practitioners' feline retrovirus management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Clinical aspects of feline immunodeficiency and feline leukemia virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Clinical aspects of feline retroviruses: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Pharmacological inhibition of feline immunodeficiency virus (FIV)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

NRTI backbone in HIV treatment: will it remain relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Feline immunodeficiency virus infection: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Testing of nucleoside analogues in cats infected with feline leukemia virus: a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

A trial with 3'-azido-2',3'-dideoxythymidine and human interferon-α in cats naturally infected with feline leukaemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Early therapy of feline leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylmethoxyethyl)adenine (PMEA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Discovery of drugs that possess activity against feline leukemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Suramin's development: what did we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Mechanism of action of foscarnet against viral polymerases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Toxicologic effects of ribavirin in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Chemokine receptors - the new frontier for AIDS research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Quantification and molecular characterization of the feline leukemia virus A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Use of recombinant interferon omega in feline retrovirosis: from theory to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Anti-retroviral effects of type I IFN subtypes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Effect of type-I interferon on retroviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

21 January 2018

Oral use of interferon

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Low-dose interferon-alpha treatment for feline immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Inhibition of feline leukemia virus replication by human leukocyte interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Immunomodulation therapy for feline leukemia virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: clinical and laboratory evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

AZT given the green light for clinical treatment of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1098612X15610676

21 January 2018

Identifiers

DOI

10.1177/1098612X15610676

1 reference

4 September 2017

1 reference

PubMed ID

26486979